JG
Therapeutic Areas
Dare Bioscience Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DARE-LARC1 | Year-long, user-controlled reversible contraception | Phase 1 |
| DARE-BV1 | Treatment of Bacterial Vaginosis (BV) | Phase 3 |
| Ovaprene | Non-hormonal, monthly intravaginal contraceptive | Phase 3 |
| DARE-HRT1 | Localized hormone therapy for Genitourinary Syndrome of Menopause (GSM) | Preclinical |
| Sildenafil Cream, 3.6% | Treatment of Female Sexual Arousal Disorder (FSAD) | Phase 2b |
Leadership Team at Dare Bioscience
SM
Sabrina Martucci Johnson
President, Chief Executive Officer & Director
JA
John A. Fair
Chief Strategy Officer, Head of Corporate Development & Investor Relations
CR
Cheryl R. Blanchard
Chief Scientific Officer
LW
Lisa Walters-Hoffert
Chief Financial Officer
DR
David R. Friend
Chief Development Officer
GW
Gregory W. Matz
Senior Vice President, Finance & Accounting, Principal Financial & Accounting Officer
DB
David B. Friend
Director
RL
Robin L. Steele
Director
RD
Roger D. Dansey
Director